Medtech Matters cover art

All Episodes

Medtech Matters — 163 episodes

#
Title
1

A Preview of MDUFA VI: Changes and Highlights, Part 2

2

A Preview of MDUFA VI: Changes and Highlights, Part 1

3

The Value in Partnering for Sterility Testing

4

ECRI's 2026 Top 10 Health Technology Hazards

5

Measuring Regulatory/Quality Team Member Performance

6

FDA's Third-Party Review Program

7

Triaging Your QMS: Considerations Based on the New QMSR

8

A Deep Dive into E&L and Biocomp Testing

9

Planning for FDA Shutdowns Now and in the Future

10

Should Wellness Products Come with a Warning?

11

3 Most Common Premarket (Postmarket?) Review Issues FDA Sees

12

Why Are One-Third of MAUDE Reports a Problem?

13

FDA Guidance on Off-Label Communication, Part 2

14

FDA Guidance on Off-Label Communication, Part 1

15

Development Considerations for OTC Medtech, Part 2

16

Development Considerations for Over-the-Counter Medtech, Part 1

17

Device Descriptions in Regulatory Submissions

18

Regulatory Ramifications Due to the Presidential Election

19

Regulatory Considerations with an Assisted Suicide Machine

20

Predetermined Change Control Plans, Part 2

21

Predetermined Change Control Plans, Part 1

22

What is a CAPA and How Do You Best Use It?

23

You Got a 483 from the FDA. Now what?

24

Revisiting Real-World Evidence

25

The Most Dangerous Devices to Hit the Market

26

Headline-Generating Medical Device Safety Concerns

27

Analyzing ECRI’s 2024 Top 10 Health Technology Hazards

28

Examining Institutional Review Boards

29

Reimbursing Breakthrough Designation Products

30

Strengthening the 510k Program

31

Medical Device Manufacturing Recalls

32

AI Predetermined Change Control Plan

33

Can You Use a Recalled Device as a Predicate?

34

Leading Issues from FDA Inspections (or History Repeating Itself)

35

To Regulate or Not to Regulate…LDTs, Part 2

36

To Regulate or Not to Regulate…Lab Developed Tests, Part 1

37

What Happens When the EUA Period Ends?

38

What Does 510k Exempt Actually Mean?

39

How Can Off-Label Use Be Promoted?

40

FDA's Intended Use Rule’s Relation to Labeling

41

Gaining an Advantage Through Class II Special Controls

42

FDA’s Refuse to Accept Policy for 510(k)s

43

Initiating a Voluntary Medical Device Recall

44

A Letter to File Deep Dive

45

Humacyte’s Bioengineered Tissue Platform Technology

46

Koya Medical Restores Mobility for Compression Therapy Patients

47

NeuroPace’s Aid in Tracking and Treating Epilepsy

48

Aidoc Is Improving Patient Outcomes Through AI

49

Performing a Gap Analysis on FDA's Regulatory Protocols

50

Stereotaxis’ Robotic Surgery System for Interventional Procedures

51

Fighting Tumors with Varian’s FLASH Technology

52

RSIP Vision’s Diagnostic Imaging Advancements

53

FDA’s Cybersecurity Playbook

54

Video Capture of Surgery with Theator

55

GE Healthcare’s Chief Digital Officer’s 2022 Predictions

56

DePuy Synthes Strives for Knee Restoration

57

Femasys Targets Fertility and Women’s Health

58

Front Line’s COBRA-OS Helps Prevent Bleed Out

59

Pristine Surgical’s Single-Use Endoscopes

60

Discussing Spine with Medtronic's Carlton Weatherby

61

Aligning Regulatory and Commercial Strategies

62

Medtech Manufacturing at the U.S.-Mexico Border

63

Surgical Instrumentation Update from Ethicon

64

De Novo Final Rule

65

Options with an Overly Burdensome FDA

66

Molli Surgical's Breast Tumor Marker

67

Three Systems of Risk

68

Glooko’s Remote Patient Monitoring for Diabetics

69

Valencell’s Wearable Biomedical Sensors

70

Regulating IVDs and LDTs

71

LifeSource Discusses Organ Donation Technologies

72

Facility Falsified Sterilization Data

73

Knobbe Martens Talks Trade Secrets

74

Canary Medical’s ‘Smart’ Implants

75

Implicity’s Cardiac Device Remote Monitoring

76

PixCell's Rapid Blood Test Diagnostics

77

Discussing Asensus Surgical’s Senhance Robotic Surgical System

78

Top 483s of 2020

79

Legacy DNA’s Market Strategy Advice

80

NeuTigers’ Edge-Based AI for Healthcare

81

Medtronic's Pillcam and GI Genius

82

COVID Diagnostics from Beckman Coulter

83

Single-Use Device Reprocessing

84

A Biomechanics Measuring Mesh

85

A Digital Stethoscope & Digital Health

86

Non-Dilutive Funding

87

BDP Reimbursement Delay

88

Robotic-Driven Percutaneous Procedures

89

Biomorphic Programmable Polymers

90

Treating Hearts Post-Attack

91

FDA’s Ambiguity on Hyaluronic Acid

92

Update on FDA's STeP Designation

93

Continuous Molecular Monitoring

94

Hologic’s Breast Health Happenings

95

Optimizing Remote Electrophysiology Monitoring

96

Medtronic's Robotic Surgery Status

97

Emergency Use Authorizations

98

Surgeons Scrubbing In Virtually

99

Talking Robotics with Zimmer Biomet

100

CDRH 2021 Priorities

101

A Non-Contact ECG Sensor

102

Communicating with the FDA

103

Talking Medtech with Joe Mullings

104

A Robotic Surgery Subscription

105

Point-of-Care Ultrasound

106

AI-Enabled Cardiac Diagnostics

107

Organ Donation Matching

108

Virtual Reality for Surgery

109

Biocompatibility and Nitinol Guidances

110

Economical Orthopedic Implants

111

Vital Signs Monitoring Via Telehealth Interface

112

Multiple Function Device Products

113

Breakthrough Designation Program Update

114

50th Episode: A Look Back

115

Combination Products Update

116

Binding vs. Nonbinding FDA Feedback

117

Real World Evidence Revisited

118

FDA Pre-Sub Best Practices

119

Scott Whitaker of AdvaMed on Medtech's Response to COVID-19

120

COVID-19, Part 2

121

COVID-19, Part 1

122

EtO Sterilization Concerns

123

FDA's eSTAR Program

124

Human Factors/Usability, Part 2

125

Human Factors/Usability, Part 1

126

Change Management, Part 2

127

Change Management, Part 1

128

Safety and Performance Based 510k

129

The Special 510k Program

130

Beyond 510(k)/PMA—Safer Technologies Program

131

Benefit-Risk Determinations

132

Mike on Medtech: Beyond 510(k)/PMA—Breakthrough Devices Program

133

Beyond 510(k)/PMA—De Novo 101

134

Mike on Medtech: The NYT Editorial Board Statement

135

The Alternative Summary Reporting Program

136

Do we need a pre-sub for 483s? (Part 2)

137

Do we need a pre-sub for 483s?

138

FDA's Material Evaluation

139

510k Modernization

140

Personalized Healthcare

141

My Holiday Wish List (Part 2)

142

My Holiday Wish List (Part 1)

143

Regulating the Practice of Medicine

144

The Bleeding Edge, Part 3

145

The Bleeding Edge, Part 2

146

The Bleeding Edge, Part 1

147

Breakthrough Designation Program

148

15 Tips for Getting New Products Through FDA

149

Voice-Enabled Medtech

150

Changing Pathway to Market?

151

3D Printing Healthcare at the Point of Care

152

Quality vs. Regulatory

153

The 'New' Alternative 510k

154

Regulatory Approval Pathway for Biomaterials

155

Pre-Sub with the FDA

156

Human Factors

157

MDUFA IV and Its Impact on Medtech Innovation

158

Off-Label Use

159

Biomaterials, Biocompatibility, and Bioabsorbable

160

3D Printing in Healthcare

161

Reimbursement for Engineers

162

Device Incident Reporting

163

Real World Evidence